187 related articles for article (PubMed ID: 977945)
1. Leukocyte-derived complement inhibitor. IV. The functional properties of C1 bound to erythrocytes pretreated with leukocyte culture supernatant.
Bernard A; Walter W; Teshima H; Boumsell L; Good RA; Day NK
J Immunol; 1976 Oct; 117(4):1117-26. PubMed ID: 977945
[TBL] [Abstract][Full Text] [Related]
2. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
3. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
[TBL] [Abstract][Full Text] [Related]
4. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion.
Tas SW; Klickstein LB; Barbashov SF; Nicholson-Weller A
J Immunol; 1999 Nov; 163(9):5056-63. PubMed ID: 10528211
[TBL] [Abstract][Full Text] [Related]
5. Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.
Kilchherr E; Schumaker VN; Phillips ML; Curtiss LK
J Immunol; 1986 Jul; 137(1):255-62. PubMed ID: 3486914
[TBL] [Abstract][Full Text] [Related]
6. Trinitrophenylated red cells (E-TNP) as a model for antibody-independent activation of the complement system via the classical pathway.
Loos M; Thesen R
J Immunol; 1978 Jul; 121(1):24-8. PubMed ID: 670702
[TBL] [Abstract][Full Text] [Related]
7. Complement activation by immunoglobulin does not depend solely on C1q binding.
Bindon CI; Hale G; Waldmann H
Eur J Immunol; 1990 Feb; 20(2):277-81. PubMed ID: 2311645
[TBL] [Abstract][Full Text] [Related]
8. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
Ziccardi RJ
J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
[TBL] [Abstract][Full Text] [Related]
9. Characterization of C1q by monoclonal antibodies.
Heinz HP; Loos M
Behring Inst Mitt; 1984 Nov; (76):42-58. PubMed ID: 6335397
[TBL] [Abstract][Full Text] [Related]
10. Antibody-independent C1 activation by E. coli.
Tenner AJ; Ziccardi RJ; Cooper NR
J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
[TBL] [Abstract][Full Text] [Related]
11. The relationship between the binding ability and the rate of activation of the complement component C1.
Folkerd EJ; Gardner B; Hughes-Jones NC
Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
[TBL] [Abstract][Full Text] [Related]
12. The effect of specific antibody on antibody-independent interactions between E. coli J5 and human complement.
Betz SJ; Page N; Estrade C; Isliker H
J Immunol; 1982 Feb; 128(2):707-11. PubMed ID: 7033382
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the hemolytic activity of the first component of complement C1 by an Escherichia coli C1q binding protein.
van den Berg RH; Faber-Krol MC; van de Klundert JA; van Es LA; Daha MR
J Immunol; 1996 Jun; 156(11):4466-73. PubMed ID: 8666822
[TBL] [Abstract][Full Text] [Related]
14. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
Pearlstein E; Sorvillo J; Gigli I
J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
[TBL] [Abstract][Full Text] [Related]
15. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor.
Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P
Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213
[TBL] [Abstract][Full Text] [Related]
16. Complement inhibitor(s) released by leukocytes. III. Evidence for a "new" C1 inhibitor in the supernatants of short-term cultures of mouse spleen and thymus cells.
Bernard A; Boumsell L; Borsos
J Immunol; 1975 Oct; 115(4):1091-4. PubMed ID: 1176767
[TBL] [Abstract][Full Text] [Related]
17. Lysis of sensitized sheep erythrocytes in human sera deficient in the second component of complement.
Knutzen Steuer KL; Sloan LB; Oglesby TJ; Farries TC; Nickells MW; Densen P; Harley JB; Atkinson JP
J Immunol; 1989 Oct; 143(7):2256-61. PubMed ID: 2506280
[TBL] [Abstract][Full Text] [Related]
18. Prevention of immune precipitation by purified classical pathway complement components.
Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
[TBL] [Abstract][Full Text] [Related]
19. Secreted chondroitin sulfate proteoglycan of human B cell lines binds to the complement protein C1q and inhibits complex formation of C1.
Kirschfink M; Blase L; Engelmann S; Schwartz-Albiez R
J Immunol; 1997 Feb; 158(3):1324-31. PubMed ID: 9013976
[TBL] [Abstract][Full Text] [Related]
20. Complement inhibitor(s) released by leukocytes. I. Pretreatment of sheep erythrocytes with supernatants of mouse spleen and thymus cells inhibit whole complement activity and C2 utilization.
Bernard A; Boumsell L; Borsos T; Good RA; Day NK
J Immunol; 1975 Oct; 115(4):1087-90. PubMed ID: 1176766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
